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Background
For a decade researchers have been searching for modi-
fier genes in individuals with a molecular diagnosis of
Lynch syndrome but the task has proven difficult as dis-
cordant results seem to be the rule rather than the
exception. Recently, two colorectal cancer (CRC) sus-
ceptibility loci have been found to be significantly asso-
ciated with an increased risk of CRC in Dutch Lynch
syndrome patients irrespective of which gene was
mutated. In a combined study of CRC risk in Australian
and Polish Lynch syndrome patients only MLH1 muta-
tion carriers were found to be at increased risk of dis-
ease. A combined analysis of the three datasets was
performed to better define this association.
Methods
The three populations combined totalled 1359 indivi-
duals from 425 families with a molecular diagnosis of
Lynch syndrome. To date, this represents the largest
Lynch syndrome cohort examined for modifier genes.
Seven SNPs, from 6 different CRC susceptibility loci,
were genotyped by both research groups and the data
analysed collectively.
Results
Individuals with MLH1 mutations harbouring the CC
(variant) genotype of SNP rs3802842 are at increased
risk of CRC (HR=2.77, p<0.001) and develop CRC on
average 11 years earlier than individuals with the AA
(wild type) genotype. All females (MLH1, MSH2 and
MSH6 mutation carriers) carrying the CC genotype of
SNP rs3802842 are at increased risk of CRC (HR=2.16,
p=0.005), while female MLH1 mutation carriers are at
highest risk (HR=3.88, p<0.001).
To investigate whether a cluster of risk alleles
increases the risk of CRC, SNP rs3802842 was combined
with the other six SNPs additively. MLH1 mutation car-
riers harbouring 3 risk alleles for SNP combination;
rs3802842 (11q23.1) + rs16892766 (8q23.3) display an
increased risk of CRC (HR=5.67, p=0.001) and an
immense difference in the age of diagnosis of CRC of 28
years is observed compared to individuals with 0 risk
alleles. While SNP combination; rs3802842 +
rs10795668 (10p14) displays an increased risk of CRC
for all females harbouring 4 risk alleles (HR=5.52,
p=0.003).
Conclusion
These results confirm the role of modifier genes in
HNPCC. We recommend that Lynch syndrome patients
with MLH1 mutations and all Lynch syndrome females
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sonalised risk assessment and tailored surveillance pro-
gram can be offered to patients at increased risk of CRC
and therefore likely to develop their CRCs at much
younger ages than the average age of disease onset.
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